Linked Life Data

20680269

Source:http://linkedlifedata.com/resource/pubmed/id/20680269

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-11-9
pubmed:abstractText
Dysregulation of histone acetylation associated with an up-regulation of histone deacetylase (HDAC) activity is common in malignant tumours. Therefore, HDAC inhibitors were developed whose effects on proliferation and apoptosis have been shown in different tumour entities. Since non-iodide-concentrating thyroid carcinomas represent a therapeutic problem, this study addressed the effects of the HDAC inhibitor MS-275 on thyroid carcinoma cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1619-7089
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2286-97
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.
pubmed:affiliation
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ) and University of Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany. a.altmann@dkfz.de
pubmed:publicationType
Journal Article